



**Matthias Pfisterer**

**Kontakt**

Matthias Pfisterer

## Publikationen (18)

Stöhr R, Sanders-van Wijk S, Pfisterer M, Jeker U, Schuh A, Leibundgut G, Maeder M, Heine G, Brandenburg V, Brunner-La Rocca H. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial. *Eur J Heart Fail* 2020

Simonavičius J, van Empel V, Knackstedt C, Puronaitė R, Čelutkienė J, Pfisterer M, Kaufmann B, Pfister O, Maeder M, Rickenbacher P, Sanders van-Wijk S, Brunner-La Rocca H. Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. *Am J Med* 2019; 132:e679-e692.

Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuillomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. *PLoS one* 2019; 14:e0210821.

Steinmann E, Brunner-La Rocca H, Maeder M, Kaufmann B, Pfisterer M, Rickenbacher P. Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. *Eur J Intern Med* 2018

Rickenbacher P, Kaufmann B, Maeder M, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca H. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). *Eur J Heart Fail* 2017

Vassalli G, Pedrazzini G, Pfisterer M, Kaiser C, Moccetti T, Bonetti P, Bertel O, Hornig B, Rickli H, Eberli F, Erne P, Galatius S, De Servi S, Klersy C, BASKET-PROVE Investigators. Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial. *Am Heart J* 2015; 173:1-7.

Zurek M, Brunner-La Rocca H, Pfisterer M, Jeker U, Handschin R, Abbühl H, Sanders-van Wijk S, Muzzarelli S, Rickli H, Maeder M, TIME-CHF Investigators. Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF. *J Card Fail* 2015

Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. *Circulation* 2014; 131:74-81.

Jensen M, Galatius S, Pfisterer M, Erne P, De Servi S, Bertel O, Fahrni G, Zurek M, Rickli H, Soerensen R, Pedersen S, Jensen J, Iversen A, Wanitschek M, Alber H, Sandsten K, Kaiser C, BASKET-PROVE Investigators. Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial. *Int J Cardiol* 2013; 168:3802-6.

Maeder M, Brunner-La Rocca H, Pfisterer M, Peter M, Vuillomenet A, Erne P, Gutmann M, Abbühl H, Rickli H, Rickenbacher P, TIME-CHF Investigators. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). *Eur J Heart Fail* 2013; 15:1148-56.

Jeger R, Gilgen N, Vuillomenet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAseL Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. *Am Heart J* 2012; 163:136-41.e1.

Kaiser C, Pfisterer M, Ricard I, Brunner-La Rocca H, De Servi S, Bonetti P, Bertel O, Hornig B, Pedrazzini G, Rickli H, Alber H, Eberli F, Erne P, Galatius S, BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. *N Engl J Med* 2010; 363:2310-9.

Muzzarelli S, Brunner-La Rocca H, Pfisterer M, Buser P, Jeker U, Gutmann M, Handschin R, Rickli H, Maeder M, Leibundgut G, TIME-CHF Investigators. Predictors of early readmission or death in elderly patients with heart failure. *Am Heart J* 2010; 160:308-14.

Pfisterer M, Brunner-La Rocca H, Schindler R, Hilti P, Schieber M, Osterhues H, Suter T, Yoon S, Beer H, Dubach P, Jeker U, Vuillomenet A, Rickenbacher P, Erne P, Gutmann M, Rickli H, Buser P, TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. *JAMA : the journal of the American Medical Association* 2009; 301:383-92.

Pfisterer M, Kaiser C, De Servi S, Rickli H, Pedrazzini G, Pachinger O, Kiowski W, Hornig B, Galatius S, Erne P, Eberli F, Brunner-La Rocca H, Bonetti P, Bertel O, BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. *American heart journal* 2008; 155:609-14.

Bernheim A, Pfisterer M, Buser P, Linka A, Kaiser C, Kiencke S, Eckstein J, Brunner-La Rocca H, Schaer B, Burger P, Sticherling C, Ammann P, Osswald S. Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing. *Journal of the American College of Cardiology* 2005; 45:1482-7.

Ammann P, Pfisterer M, Fehr T, Rickli H. Raised cardiac troponins. *BMJ (Clinical research ed.)* 2004; 328:1028-9.

Filipovic M, Jeger R, Probst C, Girard T, Pfisterer M, Gürke L, Skarvan K, Seeberger M. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. *Journal of the American College of Cardiology* 2003; 42:1767-76.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)